GLP-1R (40mg)

Manufactured in the USA by a Licensed Pharmaceutical Facility
Veteran Operated Company

GLP1-R is a next-generation investigative peptide designed to simultaneously activate three key metabolic receptors: GLP-1, GIP, and glucagon receptors. This triple-agonist profile makes GLP1-R a highly valued compound in advanced metabolic research, where scientists explore interactions between multi-hormonal pathways, appetite-regulation systems, and energy-expenditure signaling cascades.

Laboratory studies frequently examine GLP1-R for its ability to model complex metabolic processes more comprehensively than single-pathway analogs. Its balanced receptor-binding structure allows researchers to investigate coordinated hormonal feedback, nutrient-response models, and extended-duration peptide activity in controlled environments. Because of its multi-receptor engagement, GLP1-R is often selected for studies focused on the interconnected nature of metabolic and endocrine-driven regulatory pathways.

Each batch of Nova9 GLP1-R is manufactured in a licensed U.S. pharmaceutical facility and verified at ≥99% purity, ensuring reproducibility, structural integrity, and stability for research requiring precise peptide compositions. Supplied as a high-quality lyophilized powder, it is engineered for metabolic-biology laboratories conducting advanced peptide pathway modeling.

Made in the USA by a Licensed Pharmaceutical Facility
Veteran Operated Company

For Research Use Only. Not for human consumption, not for veterinary use, and not for diagnostic or therapeutic purposes. All customers certify these materials will be used solely in controlled laboratory environments.